Tumours, such as some breast and ovarian cancers, can express the marker HER2. HER2 is responsible for cancer growth and is ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...

A study has established the importance of immunoglobulin A, an antibody that is part of the immune system, in generating a response to pneumonia vaccines. Researchers have found that the absence of ...

Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...